Sertraline response

Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of major depressive and anxiety disorders, and may be used to treat other psychiatric conditions. Sertraline is in part metabolized by cytochrome P450 2C19 (CYP2C19) and variations in CYP2C19 may affect drug exposure. CYP2C19 poor metabolizers might exhibit reduced oral clearance of sertraline and side effects in CYP2C19 poor metabolizers have also been reported to be more frequent than in normal metabolizers. Therapeutic guidelines for the SSRI sertraline based on CYP2C19 genotype have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website.

PharmGKB